Press release
Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc
Alzheimer's disease Pipeline Insight
According to DelveInsight, the Alzheimer's Disease treatment pipeline includes over 110 prominent companies actively engaged in developing more than 120 therapeutic candidates for the condition.
Alzheimer's Disease Overview:
Alzheimer's disease (AD) is a progressive neurodegenerative condition and the most common cause of dementia, marked by a decline in cognitive abilities and daily functioning. It is a multifactorial disease, with two primary theories explaining its development: the cholinergic hypothesis and the amyloid hypothesis. A range of risk factors-such as aging, genetics, traumatic brain injuries, vascular conditions, infections, and environmental factors-are believed to play a role in its onset.
From a pathological perspective, AD is characterized by two types of brain lesions: (1) **positive lesions**, including amyloid plaques, neurofibrillary tangles, and other abnormal protein accumulations; and (2) **negative lesions**, which reflect brain shrinkage caused by the loss of neurons, synapses, and neuropil. Additional contributors to disease progression include neuroinflammation, oxidative stress, and cholinergic system damage.
Clinically, AD is divided into three stages based on cognitive decline: preclinical, mild cognitive impairment, and dementia. The condition often begins with short-term memory issues and gradually impairs decision-making, judgment, and other executive functions. As it advances, patients experience worsening language and visual-spatial skills, along with behavioral and psychiatric symptoms such as apathy, agitation, and psychosis. In the later stages, motor dysfunction, disrupted sleep, and complete physical dependence become common, requiring continuous care and support.
Request for a detailed insights report on Alzheimer's Disease pipeline insights @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Alzheimer's Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer's Disease Therapeutics Market.
Key Takeaways from the Alzheimer's Disease Pipeline Report
*
DelveInsight's Alzheimer's Disease pipeline report depicts a robust space with 110+ active players working to develop 120+ pipeline therapies for Alzheimer's Disease treatment.
*
In September 2025, Japan's Ministry of Health, Labour, and Welfare approved KISUNLA (donanemab-azbt, 350 mg/20 mL) for intravenous infusion every four weeks. Developed by Eli Lilly, this drug is aimed at treating adults with early symptomatic Alzheimer's disease, including mild dementia, who have confirmed amyloid pathology.
*
In July 2025, the FDA granted approval to Eli Lilly's donanemab, an anti-amyloid antibody, making it the third drug aimed at modifying the progression of Alzheimer's disease. This approval is set to increase competition between Eli Lilly's donanemab and Biogen and Eisai's ADUHELM (aducanumab) and LEQEMBI (lecanemab).
*
Key Alzheimer's Disease companies such as AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others are evaluating new drugs for Alzheimer's Disease to improve the treatment landscape.
*
Promising Alzheimer's Disease pipeline therapies in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and others.
Alzheimer's Disease Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Alzheimer's Disease Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer's Disease market.
Download our free sample page report on Alzheimer's Disease pipeline insights @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Alzheimer's Disease Emerging Drugs
*
AR1001: AriBio Co., Ltd.
*
NE3107: BioVie
*
LY3372689: Eli Lilly & Co.
*
CT1812: Cognition Therapeutics
*
ABBV-916: AbbVie Inc.
*
ALX-001: Allyx Therapeutics, Inc.
Alzheimer's Disease Companies
More than 110 major companies are actively developing treatments for Alzheimer's disease. Among these, AriBio Co., Ltd. and BioVie have drug candidates that are in the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 120+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Alzheimer's Disease Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer's Disease Therapies and Key Companies: Alzheimer's Disease Clinical Trials and advancements [https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Alzheimer's Disease Pipeline Therapeutic Assessment
- Alzheimer's Disease Assessment by Product Type
- Alzheimer's Disease By Stage
- Alzheimer's Disease Assessment by Route of Administration
- Alzheimer's Disease Assessment by Molecule Type
Download Alzheimer's Disease Sample report to know in detail about the Alzheimer's Disease treatment market @ Alzheimer's Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Alzheimer's Disease Current Treatment Patterns
4. Alzheimer's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Alzheimer's Disease Late-Stage Products (Phase-III)
7. Alzheimer's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alzheimer's Disease Discontinued Products
13. Alzheimer's Disease Product Profiles
14. Alzheimer's Disease Key Companies
15. Alzheimer's Disease Key Products
16. Dormant and Discontinued Products
17. Alzheimer's Disease Unmet Needs
18. Alzheimer's Disease Future Perspectives
19. Alzheimer's Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Alzheimer's Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-aribio-co-ltd-eli-lilly-co-cognition-therapeutics-abbvie-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc here
News-ID: 4084084 • Views: …
More Releases from ABNewswire
How DarioHealth Quietly Became One of the Most Intriguing Setups in Digital Heal …
TL;DR: A growing $69M pipeline, new independently validated outcomes, and accelerating employer adoption now point to a company that may be entering an inflection phase that the market doesn't yet seem to recognize (NASDAQ: DRIO)
Digital health has not been kind to investors. The last cycle produced too many companies that scaled too quickly, burned too much capital, and never proved that their solutions could actually bend the medical cost curve.…
Vegas Home Buyers Offers a Fast Cash Option for Homeowners Selling Houses in Las …
Image: https://www.abnewswire.com/upload/2025/11/f5ae9beaa45bcaf101121e1675b7ba18.jpg
Vegas Home Buyers [https://www.vegashb.com/], a family-owned real estate company, continues to provide homeowners across the Las Vegas valley with a straightforward, stress-free way to sell their homes fast for cash without repairs, agent fees, or long waiting periods. Founded by Kostika Xhurka, the company was created to give homeowners a simple option when a traditional sale doesn't fit their situation.
Selling a house in Las Vegas often involves showings, inspections,…
Cardiff Care Workers Missing Out on Uniform Tax Refunds
Many Cardiff care workers are missing out on tax relief for uniforms. Pie's HMRC-compliant PAYE tax rebate app makes it easy to reclaim money owed, simplifying the process and ensuring carers receive the refunds they deserve.
CARDIFF, United Kingdom - 17 November, 2025 - Thousands of Cardiff care workers are failing to claim tax relief on work-related uniforms, leaving hundreds of pounds unclaimed each year. Many carers are unaware they are…
Liverpool Small Businesses Go Digital to Beat Tax Deadlines
Pie Money Limited is a UK-based fintech company transforming how individuals and small businesses manage and file taxes. With real-time calculations, intuitive design, and HMRC-compliant filing, Pie helps users stay stress-free and fully compliant throughout the tax year.
LIVERPOOL, United Kingdom - 17 November, 2025 - Liverpool's small business community is embracing digital tax tools at record speed as Making Tax Digital (MTD) requirements continue to reshape the way SMEs manage…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
